Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Maternal exposure timing unspecified? 103 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 103 reports of Maternal exposure timing unspecified have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.2% of all adverse event reports for OCRELIZUMAB.

103
Reports of Maternal exposure timing unspecified with OCRELIZUMAB
0.2%
of all OCRELIZUMAB reports
1
Deaths
10
Hospitalizations

How Dangerous Is Maternal exposure timing unspecified From OCRELIZUMAB?

Of the 103 reports, 1 (1.0%) resulted in death, 10 (9.7%) required hospitalization.

Is Maternal exposure timing unspecified Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 103 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Maternal exposure timing unspecified?

RITUXIMAB (402) METHOTREXATE (350) ADALIMUMAB (343) DICLOFENAC (331) TOCILIZUMAB (327) HYDROXYCHLOROQUINE (309) FOLIC ACID (304) INFLIXIMAB (303) LEFLUNOMIDE (302) SECUKINUMAB (301)

Which OCRELIZUMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Maternal exposure timing unspecified Reports All Drugs Causing Maternal exposure timing unspecified OCRELIZUMAB Demographics